Viridian Therapeutics Inc
VRDN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.49B
Close$
$-10.02
146.4% downside
Current Fair Value
146.4% downsideOvervalued by 146.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.49 Billion |
|---|---|
| Enterprise Value | $2.57 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.32 |
| Beta | 0.96 |
| Outstanding Shares | 107,884,104 |
Return
| Return on Equity | -58.45% |
|---|---|
| Return on Assets | -35.27% |
| Return on Invested Capital | -37.63% |
Valuation & Multiples
| P/E Ratio | -6.23 |
|---|---|
| PEG | -23.8 |
| Price to Sales | - |
| Price to Book Ratio | 3.6 |
| Enterprise Value to Revenue | 36.13 |
| Enterprise Value to EBIT | -6.61 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.03
Average shareholder expectationRevenue Estimate
$56,364
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.99
Average shareholder expectationRevenue Estimate
$4.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2155▼ 124.64% |
|---|---|
| Total Calls | 421,400▲ 37.17% |
| Total Puts | 90,800▼ 79.78% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 126.86%▲ 16.91% |
|---|---|
| Total Invested | $2.52B▲ 13.71% |
| Investors Holding | 227▼ 3.00% |
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...